Condition
Childhood Hepatoblastoma
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01336881CompletedPrimary
Biomarkers in Tissue Samples From Young Patients With Liver Cancer
NCT00831844Phase 2Completed
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
NCT00003994Phase 3CompletedPrimary
Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
NCT00091182Phase 2Completed
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Showing all 4 trials